Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

Ginkgo Bioworks (NYSE: DNA ) stock is on the move Tuesday after the company announced a continued partnership with Novo Nordisk (NYSE: NVO ). These two companies have been working together on the development of expression systems for pharmaceutical products.

DNA Stock Alert: Ginkgo Bioworks Moves Forward With Novo Nordisk Partnership

BOSTON , July 11, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products. With the pilot phase completed and the first milestone achieved, the two companies will now move into the development phase to work towards making a more effective production process.

Ginkgo Bioworks Advances Collaboration with Novo Nordisk on Expression Systems for Pharmaceutical Products

Ambrosia aims to make the production of allulose, a next-generation sugar replacement, more scalable and affordable JERUSALEM and BOSTON , June 29, 2023  /PRNewswire/ -- Ambrosia Bio, an Israeli foodtech company developing novel bioprocesses for the global sugar replacement industry, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ambrosia Bio will leverage Ginkgo Enzyme Services , including its proprietary chassis organisms, to develop an expression strain for the scalable production of the Ambrosia Bio proprietary enzymes used for the conversion of feedstock into allulose. Allulose is an FDA-approved rare sugar that is found in figs, raisins, wheat, maple syrup, and molasses but occurs naturally only in small amounts.

Ambrosia Bio Leverages Ginkgo Enzyme Services to Develop a More Scalable Enzymatic Process for Allulose

Nextdoor

Lilium BV

Picture this: you're holding a golden ticket that could multiply your modest investment into a colossal windfall—almost overnight. It sounds like a fairytale, right?

Are Penny Stocks Worth It? 3 To Watch Right Now

LOS ANGELES and BOSTON , June 28, 2023 /PRNewswire/ -- Voodoo Scientific, a company creating capabilities to help distillers deliver meaningful innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced Voodoo's plans to leverage Ginkgo Enzyme Services to optimize an enzymatic solution to enable distillers to produce ultra-premium spirit products that are truly smooth. To support the development of the enzyme critical to Voodoo's product, Ginkgo will leverage its  extensive protein   discovery and design capabilities to design and optimize the enzyme for a wide range of conditions in spirits manufacturing, from craft to global-scale production environments.

Voodoo Scientific Leverages Ginkgo Enzyme Services to Develop Enzymatic Processing Aid to Eliminate the Harsh "Bite" from Distilled Alcoholic Beverages

Plug Power

Plug Power and Ginkgo Bioworks are two long-term plays with significant growth potential. According to analysts' price targets, these stocks could nearly double in value.

2 Growth Stocks Wall Street Thinks Can Soar 90%

The report, Caring at Ginkgo, demonstrates Ginkgo's commitment and contributions to environmental, societal and governance matters BOSTON , June 22, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today published its 2022 Sustainability Report, Caring at Ginkgo , detailing the company's views and progress towards addressing global challenges, such as climate change and biological threats, as well as outlining the practices supporting the organization's commitment to thoughtfully deploy its platform, build a diverse and inclusive workforce, and continue to foster a culture of employee ownership. "Synthetic biology gives us a key tool to address some of the major societal and environmental challenges the world faces today," said Jason Kelly, CEO and co-founder, Ginkgo Bioworks.

Ginkgo Bioworks 2022 Sustainability Report Highlights Progress Towards a More Sustainable and Inclusive Future

By leveraging Ginkgo's ultra high throughput encapsulated screening capabilities, AgBiome aims to unlock even higher performance of its microbial strain pipeline RESEARCH TRIANGLE PARK, N.C. and BOSTON , June 6, 2023 /PRNewswire/ -- AgBiome ® , Inc., a leader in global microbial innovation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to optimize the performance of products in AgBiome's pipeline of agricultural biologicals.

AgBiome Leverages Ginkgo Strain Optimization Services to Optimize Agricultural Biological Pipeline

BOSTON , June 5, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that management is scheduled to participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference, on June 12, 2023, at 4:40 p.m. PT. Further details, a webcast link, and a replay of the fireside chat will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

Ginkgo Bioworks Announces Participation in Goldman Sachs 44th Annual Global Healthcare Conference

RIJSWIJK, Netherlands and BOSTON , May 25, 2023 /PRNewswire/ -- Centrient Pharmaceuticals ("Centrient"), the global business-to-business leader in sustainable antibiotics, next-generation statins and anti-fungals, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced they are expanding their existing partnership aimed at broadening Centrient's portfolio of environmentally friendly active pharmaceutical ingredients (APIs), following the success of previous work together. Ginkgo's ongoing partnership with Centrient focuses on improving the sustainability of fermentation and enzymatic syntheses of beta-lactam antibiotic APIs.

Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API Space

Cathie Wood is continuing to buy shares of Ginkgo Bioworks. The biofoundry's platform is scaling up, and customers are flocking.

3 Reasons Why Cathie Wood Is Buying Ginkgo Bioworks Stock Hand Over Fist

Altus Power

Standard BioTools Inc

Marqeta

Movella Holdings Inc

FiscalNote Holdings Inc

Porch Group

If you're curious about penny stocks, they offer an interesting niche. Whether you're new to trading these stocks or expanding your investment style, understanding what to look for and how to build a strong watch list is obviously important.

7 Top Penny Stocks To Buy According To Insiders In May 2023

When it comes to investing, penny stocks have become an interesting niche. If you're new to trading these types of stocks, it's important to understand what your looking for and how to find it in order to put together a strong list of penny stocks to watch.

4 Top Penny Stocks To Buy According To Insiders In May 2023

Moderna

Viking Therapeutics

These biotech stocks are swinging for the fences. They may hit homers, they may strike out.

Hero or Zero? 3 High-Risk Biotech Stocks to Make You Rich

23andMe

Schrodinger 

Artificial intelligence is becoming an important value-add for collaborations. Some companies are pursuing collaboration-targeted business models.

3 Key Biotech Trends for 2023 And Beyond

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President, Corporate Development Jason Kelly - Co-Founder & Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Gaurav Goparaju - Berenberg Bank Ivy Kozlowski - Goldman Sachs Anna Marie Wagner Good afternoon. I'm Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2023 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.05 per share a year ago.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates

Ginkgo Bioworks (NYSE: DNA ) just reported first quarter results for 2023. Ginkgo Bioworks reported a loss per share of 11 cents.

DNA Stock Earnings: Ginkgo Bioworks Misses EPS, Beats Revenue Estimates

Ginkgo added 13 new Cell Programs to the Foundry platform in Q1 2023 Recent acquisition of the adeno-associated virus (AAV) capsid engineering platform assets of StrideBio is advancing Ginkgo's capabilities and commercial potential in gene therapy Ginkgo ended Q1 2023 with approximately $1.2 billion in cash and cash equivalents - this strong balance sheet is a strategic asset that provides Ginkgo with a multi-year runway and a margin of safety in an otherwise challenging market environment BOSTON , May 10, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2023. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports First Quarter 2023 Financial Results

COPENHAGEN, Denmark and BOSTON , May 9, 2023 /PRNewswire/ -- Octarine Bio, a synthetic biology company developing new sustainable bio-based ingredients, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a multi-stage partnership focused on compounds in the tryptophan pathway, with the objective of engineering a strain for producing violacein and its derivatives, a naturally occurring bis-indole pigment with potent bioactive properties including anti-microbial, anti-oxidant, and UV protective properties. Although initially focused on violacein, the collaboration has the potential to expand to other tryptophan-derived compounds, each with their own unique applications.

Octarine Bio and Ginkgo Bioworks Announce Partnership to Produce Natural Colors

Grab Holdings Ltd

Invitae

Trevena

Are these the best penny stocks to buy right now? Here's what's moving on Monday.

Best Penny Stocks To Buy Now? 4 To Watch Before May CPI Data

BOSTON , May 8, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim. The two companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.

Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

Mr. Coen brings over 30 years of public accounting and corporate finance leadership experience, most recently as Corporate Vice President and Corporate Controller at Charles River Laboratories Marie Fallon to step down as CAO effective May 15, 2023 BOSTON , May 5, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Steven P. Coen, CPA, a seasoned finance executive with more than 30 years of public accounting and corporate finance leadership experience, as Chief Accounting Officer ("CAO"), effective May 15, 2023.

Ginkgo Bioworks Announces Appointment of Steven P. Coen as Chief Accounting Officer

The bio-engineering companyexpects a sharp slowdown in revenue this year. Despite all of its partnerships, Ginkgo's business isn't overly diverse, suggesting it could have a hard time handling an economic downturn.

Down 76% From Its High, Can Ginkgo Bioworks Stock Turn Things Around?

BOSTON , May 4, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 16-20, in Los Angeles. Ginkgo will present data on its high-throughput screening platform for chimeric antigen receptor (CAR) libraries, which can enable discovery of CAR variants with desired characteristics.

News for Ginkgo Bioworks Holdings Stock (DNA)